Limitations in current treatment options, particularly in LGG and AML, due to both inefficacy and systemic toxicity, make mutant IDH (mutIDH), and its associated molecular pathways attractive therapeutic targets (7–9). This evidence concerns the gene IDH2 and acute myeloid leukemia.